OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 70 filers reported holding OCULAR THERAPEUTIX INC in Q2 2019. The put-call ratio across all filers is 1.35 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,901 | -69.0% | 12,389 | -49.1% | 0.00% | – |
| Q2 2023 | $125,486 | -2.1% | 24,319 | 0.0% | 0.00% | – |
| Q1 2023 | $128,161 | +19318.3% | 24,319 | -89.6% | 0.00% | – |
| Q4 2022 | $660 | -99.9% | 234,783 | +60.7% | 0.00% | – |
| Q3 2022 | $607,000 | +39.9% | 146,122 | +35.5% | 0.00% | – |
| Q2 2022 | $434,000 | +422.9% | 107,812 | +544.7% | 0.00% | – |
| Q1 2022 | $83,000 | -29.1% | 16,723 | 0.0% | 0.00% | – |
| Q4 2021 | $117,000 | +234.3% | 16,723 | +46.4% | 0.00% | – |
| Q3 2019 | $35,000 | -30.0% | 11,423 | 0.0% | 0.00% | – |
| Q2 2019 | $50,000 | -47.4% | 11,423 | -52.1% | 0.00% | – |
| Q1 2019 | $95,000 | 0.0% | 23,831 | 0.0% | 0.00% | – |
| Q4 2018 | $95,000 | -52.5% | 23,831 | -18.1% | 0.00% | – |
| Q3 2018 | $200,000 | +13.0% | 29,090 | -26.7% | 0.00% | – |
| Q4 2017 | $177,000 | -27.8% | 39,664 | 0.0% | 0.00% | – |
| Q3 2017 | $245,000 | – | 39,664 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
| Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
| DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
| Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
| GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
| Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
| Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
| Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
| Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |